Efficiency of SIRT2 transfection
Western blot analysis of diquat treated SH-SY5Y cells showed a significant increase in SIRT2 levels in SIRT2 transfected cells with a 3-3.5 fold increase in vehicle (0.2% PBS) treated cells compared to the empty vector transfected cells (p<0.001 compared to both empty vector and empty vector+AGK2, Supplementary Figure 1) . Similar increase was seen in 10μM diquat treated cells, interestingly a small increase of 12% in SIRT2 levels was observed in SIRT2 SIRT2 was over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one set of cells was treated with toxin alone and another with SIRT2 inhibitor AGK2 and toxin. Cells were harvested and the samples were probed for SIRT2 expression; a-d show the representative blot of SIRT2 and GAPDH in cells treated with a) 20μM diquat, b) 10μM diquat, c) 20μM rotenone and d) 0.5μM rotenone. e-h represent the data are presented as fold-untreated (+SD) in cells treated with a) 20μM diquat, b) 10μM diquat, c) 20μM rotenone and d) 0.5μM rotenone. Data presented are from three independent assays (n=3). *p<0.05 when compared to 0.2% PBS/DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 and ~p<0.05 when compared to empty vector + AGK2 treatment and $$$p<0.001 and $$p<0.01 when compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferronicorrected).
Efficiency of SIRT2 inhibition
In order to test the efficiency of SIRT2 inhibition by AGK2, levels of acetylated α-tubulin (K40), was measured in the samples. As shown in Supplementary Figure 2 SIRT2 was over-expressed in SH-SY5Y cells and control cells were transfected with empty vector following which one set of cells was treated with toxin alone and another with SIRT2 inhibitor AGK2 and toxin. Cells were harvested and the samples were probed for α-tubulin expression; a and c show the representative blot of α-tubulin, acetylated α-tubulin and GAPDH in cells treated with a) 20μM diquat or 10μM diquat and c) 20μM rotenone or 0.5μM rotenone. The graphs represent the data are presented as fold-untreated (+SD) in cells treated with b) 20μM diquat or 10μM diquat, d) 20μM rotenone or 0.5μM rotenone. Data presented are from three independent assays (n=3). *p<0.05 when compared to 0.2% PBS/DMSO, one-way ANOVA (Bonferroni corrected), ###p<0.001and ##p<0.01 when compared to empty vector treatment, ~~~p<0.001 and ~p<0.05 when compared to empty vector + AGK2 treatment and $$$p<0.001 and $$p<0.01 when compared to SIRT2 overexpressing cells, two-way ANOVA (Bonferroni-corrected). Recombinant SIRT1, SIRT2 or SIRT3 was used in the activity assay at 100ng/well and at a dose range of 1µM-60µM for AGK2 in order to define the inhibitory characteristics of AGK2 as a specific SIRT2 inhibitor. AGK2 showed highly selective inhibition of SIRT2 up to 60µM.
The efficiency of the substrate Ac-RHKK(Ac)-AMC to measure SIRT activity was also analysed using recombinant SIRT1, SIRT2 and SIRT3. As shown in Figure 4 , the substrate showed comparable deacetylase activity with the three recombinant SIRTs and no significant statistical difference was observed in activity of SIRT1, SIRT2 or SIRT3 (Supplementary Recombinant SIRTs were used for the activity assay at 100ng/well to measure the deacetylase activity of SIRT1-SIRT3 towards the substrate. Recombinant sirtuins showed similar specific activity using the Ac-RHKK(Ac)-AMC substrate.
Cellular distribution of SIRT2 in the human brain
The location of SIRT2 was determined in different regions of the hippocampus-CA1, CA2, CA3 and CA4. In controls, SIRT2 was localised in the nucleus in CA1 neurones ( Figure 6a) and CA2 neurones ( Figure 6b ) and was localised in both the nucleus and cytoplasm in CA3 neurones ( Figure 6c ) and CA4 neurones (Figure 6d ), whereas in PD SIRT2 was present in the cytoplasm and occasionally present in the nucleus in CA1-4 ( Figure 6 a-d) . As in PD, in PDD cases, SIRT2 was localised both in the nucleus and cytoplasm in CA1 and CA2 but was prominently in the cytoplasm in CA3 and CA4 (Figure 6 a-d 
